VERAXA Biotech Begins Trading on Nasdaq After Closing Business Combination with Voyager Acquisition Corp.

VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp., forming VERAXA Biotech AG, which began trading on the Nasdaq Capital Market on June 11, 2026, under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates (ADCs) based on its proprietary BiTAC platform, designed to selectively target cancer cells while sparing healthy tissue.

The business combination comes with significant financial backing. VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate.

This listing marks a major milestone for the biotech firm, which was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. VERAXA’s pipeline is powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, aiming to rapidly advance its ADCs and proprietary BiTAC formats into clinical development and beyond.

Voyager Acquisition Corp., the special purpose acquisition company (SPAC) that merged with VERAXA, has a mission to revolutionize the healthcare sector through mergers, stock purchases, or business combinations. Its team includes experienced executives with expertise in investing, operations, and medical innovation, supported by a vast network of connections. For more information about Voyager, visit https://www.voyageracq.com.

VERAXA’s BiTAC platform aims to address key challenges in cancer therapy by selectively engaging T cells to attack tumor cells while minimizing damage to healthy tissue. The company’s lead BiTAC-TCE candidate has shown promising preclinical results, and the new funding will help push it toward clinical trials. The company also plans to advance its BiTAC-ADC programs, which combine the targeting capabilities of antibodies with the potency of cytotoxic drugs.

Investors and industry observers will be watching how VERAXA leverages the proceeds from the business combination and financings to achieve its development milestones. The company’s ability to translate its preclinical data into clinical successes will be critical, as competition in the bispecific antibody space intensifies. For regular updates about VERAXA Biotech, visit www.veraxa.com.

The full press release can be viewed at https://ibn.fm/ka00j. This announcement contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that could cause actual results to differ materially. These risks are detailed in the company’s filings with the SEC.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Begins Trading on Nasdaq After Closing Business Combination with Voyager Acquisition Corp..

The post VERAXA Biotech Begins Trading on Nasdaq After Closing Business Combination with Voyager Acquisition Corp. appeared first on citybuzz.